CORE--ADVANCED TECHNOLOGY LABORATORIES

本提案所述研究的目的是提供核心 为艾滋病临床试验组（ACTG）研究提供病毒学实验室支持 由罗切斯特大学艾滋病临床试验单位（ACTU）进行。 据了解，一个病毒学核心实验室将有他 负责对其他ACTU进行病毒学研究。 该项目的具体目标包括：1）进行病毒学研究 在ACTG临床试验中， 试验，2）储存患者样本并保持有效库存 系统，以及3）开发，评估和采用新技术， 测量HIV感染和疾病的病毒学标志物。 技术 这些研究中建议使用的方法包括定性外周 血液单核白细胞（PBML）培养和p24抗原的测量。 申请人由ACTG的病毒参考实验室（VRL）认证 目前，该中心已完成了超过所需的500例艾滋病毒培养和2600例 每年进行p24抗原测定。 其他技术将 用于测量抗逆转录病毒效果的方法包括定量PBML 培养，定性和定量血浆培养，以及测量 使用聚合酶链反应（PCR）检测HIV前病毒DNA和病毒体RNA。 所有这些技术都是在罗切斯特大学建立的 ACTU。 虽然没有要求在RFA，罗切斯特ACTU的大学也是 准备测量艾滋病毒对抗逆转录病毒药物的敏感性，如果 对其他病毒感染进行实验室调查 这通常发生在感染艾滋病毒的患者身上。

The objective of the studies described in this proposal is to provide core virology laboratory support for AIDS Clinical Trials Group (ACTG) studies conducted by the University of Rochester AIDS Clinical Trials Unit (ACTU). It is understood that a Virology Core Laboratory would have he responsibility to conduct virologic studies for other ACTUs as well. The specific aims of this project include: 1) performing virologic studies to measure antiretroviral effects among patients enrolled in ACTG clinical trials, 2) to store patient samples and maintain an efficient inventory system, and 3) to develop, evaluate and incorporate new techniques for measurement of virologic markers of HIV infection and disease. Techniques which are proposed for use in these studies include qualitative peripheral blood mononuclear leukocyte (PBML) cultures and measurement of p24 antigen. The applicants are certified by the ACTG's Viral Reference Laboratory (VRL) and currently perform in excess of the required 500 HIV cultures and 2,600 p24 antigen determinations per year. Additional techniques which will be employed to measure antiretroviral effects include quantitative PBML cultures, qualitative and quantitative plasma cultures, and measurement of HIV proviral DNA and virion RNA using the polymerase chain reaction (PCR). All of these techniques are established at the University of Rochester ACTU. Although not requested in the RFA, the University of Rochester ACTU is also prepared to measure HIV susceptibility to antiretroviral drugs, and, if necessary, to conduct laboratory investigations of other virus infections which commonly occur in patients who are infected with HIV.